The short version of alpha-MSH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
=== NAD-II Riboswitch === The NAD⁺-II riboswitch was first described as the pnuC RNA motif, discovered via computational searches for long GC-rich intergenic regions in bacterial genomes. The original consensus model consists of two base-paired stems (P1 and P1a) separated by a conserved internal loop, with a three-nucleotide segment predicted to form a pseudoknot by base-pairing with a portion of the Shine-Dalgarno sequence of the adjacent open reading frame. Its structure was subsequently confirmed by X-ray crystallography. In contrast to the NAD⁺-I class, NAD⁺-II riboswitches specifically and robustly recognize the oxidized form of the nicotinamide moiety either as part of NMN, NR, or intact NAD⁺. The original examples were found exclusively in the genus Streptococcus, where these riboswitches regulate pnuC genes encoding an NR/NMN transporter. In contrast to the NAD⁺-I class, NAD⁺-II riboswitches specifically and robustly recognize the oxidized form of the nicotinamide moiety either as part of NMN, NR, or intact NAD⁺. The original 43 examples were found exclusively in the genus Streptococcus, where these riboswitches regulate pnuC genes encoding an NR/NMN transporter.
The main minority ethnic groups of the former Commonwealth, including Ukrainians, Lithuanians, Belarusians and Jews, were getting involved in their own national movements and plans, which met with disapproval on the part of those Polish independence activists who counted on an eventual rebirth of the Commonwealth or the rise of a Commonwealth-inspired federal structure (a political movement referred to as Prometheism). Around the start of the 20th century, the Young Poland cultural movement, centered in Austrian Galicia, took advantage of a milieu conducive to liberal expression in that region and was the source of Poland's finest artistic and literary productions. In this same era, Marie Skłodowska Curie, a pioneer radiation scientist, performed her groundbreaking research in Paris.
Resistance has in fact appeared and may be growing. But it is remarkable that despite the sharp shifts in the distribution of power, the other great powers have not yet responded in a way anticipated by balance-of-power theory.
Levomethorphan (LVM) (INN, BAN) is an opioid analgesic of the morphinan family that has never been marketed. It is the L-stereoisomer of racemethorphan (methorphan). The effects of the two isomers of racemethorphan are quite different, with dextromethorphan (DXM) being an antitussive at low doses, but a dissociative at much higher doses. Levomethorphan is about five times stronger than morphine. Levomethorphan is a prodrug to levorphanol, analogously to DXM acting as a prodrug to dextrorphan, or codeine behaving as a prodrug to morphine. As such, levomethorphan has similar effects to levorphanol but is less potent as it must be demethylated to the active form by liver enzymes before being able to produce its effects. As a prodrug of levorphanol, levomethorphan functions as a potent agonist of all three of the opioid receptors, μ, κ (κ1 and κ3 but notably not κ2), and δ, as an NMDA receptor antagonist, and as a serotonin-norepinephrine reuptake inhibitor. Via activation of the κ-opioid receptor, levomethorphan can produce dysphoria and psychotomimetic effects such as dissociation and hallucinations. Levomethorphan is listed under the Single Convention on Narcotic Drugs 1961 and is regulated like morphine in most countries. In the United States it is a Schedule II Narcotic controlled substance with a DEA ACSCN of 9210 and a 2014 annual aggregate manufacturing quota of 195 grams, up from 6 grams the year before. The salts in use are the tartrate (free base conversion ratio 0.644) and hydrobromide (0.958).
Radium has 33 known isotopes with mass numbers from 202 to 234, all of which are radioactive. Four of these – 223Ra (half-life 11.4 days), 224Ra (3.64 days), 226Ra (1600 years), and 228Ra (5.75 years) – occur naturally in the decay chains of primordial thorium-232, uranium-235, and uranium-238 (223Ra from uranium-235, 226Ra from uranium-238, and the other two from thorium-232). These isotopes nevertheless still have half-lives too short to be primordial radionuclides, and only exist in nature from these decay chains. Together with the mostly artificial 225Ra (15 d), which occurs in nature only as a decay product of minute traces of neptunium-237, these are the five most stable isotopes of radium. All other 27 known radium isotopes have half-lives under two hours, and the majority have half-lives under a minute. Of these, 221Ra (half-life 28 s) also occurs as a 237Np daughter, and 220Ra and 222Ra would be produced by the still-unobserved double beta decay of natural radon isotopes. At least 12 nuclear isomers have been reported, the most stable of which is radium-205m with a half-life between 130~230 milliseconds; this is still shorter than twenty-four ground-state radium isotopes. 226Ra is the most stable isotope of radium and is the last isotope in the (4n + 2) decay chain of uranium-238 with a half-life of over a millennium; it makes up almost all of natural radium. Its immediate decay product is the dense radioactive noble gas radon (specifically the isotope 222Rn), which is responsible for much of the danger of environmental radium.
Sources: en.wikipedia.org
Atoms and molecules of gas or liquid can be trapped on a solid surface in a process called adsorption. This is an exothermic process involving a release of heat, and heating the surface increases the probability that an atom will escape within a given time. At a given temperature
When an organic compound is fermented, it is broken down to a simpler molecule and releases electrons. The electrons are transferred to a redox cofactor, which, in turn, transfers them to an organic compound. ATP is generated in the process, and it can be formed via substrate-level phosphorylation or by ATP synthase.
USAAF Lt Col. James H. Howard of the 356th Fighter Squadron, 354th Fighter Group was awarded the Medal of Honor for his action during a bomber escort mission near Oschersleben, Germany on 11 January 1944, flying P-51B, serial number 43-6315 nicknamed "Ding Hao". Despite being outnumbered, Howard shot down three German planes and continued to defend the bombers even when his guns went out of action and fuel supply became dangerously low. USAAF Maj. William A. Shomo of the 82nd Reconnaissance Squadron, 71st Reconnaissance Group was awarded the Medal of Honor for his action during a mission over Luzon, Philippines on 11 January 1945, flying an F-6D, the armed photo reconnaissance variant of the P-51, serial number 44-14841 nicknamed "Snooks the 5th". On that mission, Shomo shot down seven Japanese planes and became an "ace in a day".
== Discovery == Identification of the 5-HT3 receptor did not take place until 1986, lacking selective pharmacological tools. However, with the discovery that the 5-HT3 receptor plays a prominent role in chemotherapy- and radiotherapy-induced vomiting, and the concomitant development of selective 5-HT3 receptor antagonists to suppress these side effects aroused intense interest from the pharmaceutical industry and therefore the identification of 5-HT3 receptors in cell lines and native tissues quickly followed.
Sources: en.wikipedia.org
The characteristic symptoms of a scabies infection include intense itching and superficial burrows. Because the host develops the symptoms as a reaction to the mites' presence over time, typically a delay of four to six weeks occurs between the onset of infestation and the onset of itching. Similarly, symptoms often persist for one to several weeks after successful eradication of the mites. As noted, those re-exposed to scabies after successful treatment may exhibit symptoms of the new infestation in a much shorter period—as little as one to four days.
== References == Carlsson, J.; Forssell Aronsson, E; Hietala, SO; Stigbrand, T; Tennvall, J; et al. (2003). "Tumour therapy with radionuclides: assessment of progress and problems". Radiotherapy and Oncology. 66 (2): 107–117. doi:10.1016/S0167-8140(02)00374-2. PMID 12648782. "Radioisotopes in Industry". World Nuclear Association. Archived from the original on 27 February 2013. Retrieved 2 May 2008. Martin, James (2006). Physics for Radiation Protection: A Handbook. John Wiley & Sons. p. 130. ISBN 978-3527406111.
He would subsequently be recognised as engaged in essential war work through his role in broadcasting for the BBC and documentary filmmaking, work he took up in 1941 after he and Caitlin moved to London, leaving their son with Caitlin's mother at Blashford. Thomas produced film scripts for the Strand Film Company, work which provided him with a much needed financial mainstay throughout the war years and his first regular source of income since working for the South Wales Daily Post. In February 1941, Swansea was bombed by the Luftwaffe in the Three Nights' Blitz. Castle Street was one of many streets that suffered badly; rows of shops, including the Kardomah Café, were destroyed. Thomas walked through the bombed-out shell of the town centre with his friend Bert Trick. Upset at the sight, he concluded: "Our Swansea has died". Thomas later wrote a feature programme for the radio, Return Journey, describing how: "The Kardomah Café was razed to the snow, the voices of the coffee drinkers—poets, painters, and musicians in their beginnings—all lost". The programme, produced by Philip Burton, was first broadcast on 15 June 1947. The Kardomah Café reopened on Portland Street after the war. In early 1943, Thomas began a relationship with Pamela Glendower, one of several affairs he had during his marriage. The affairs either ran out of steam or were halted after Caitlin discovered his infidelity. In March 1943, Caitlin gave birth to a daughter, Aeronwy, in London. They lived in a run-down studio in Chelsea, made up of a single large room with a curtain to separate the kitchen.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.